Related Experiment Videos
Reduced lung diffusion capacity after Mycoplasma pneumoniae pneumonia
E Marc1, M Chaussain, F Moulin
1Department of Pediatrics, Hôpital Saint Vincent de Paul, Paris, France.
The Pediatric Infectious Disease Journal
|August 26, 2000
Summary
Delayed diagnosis and treatment of Mycoplasma pneumoniae Community-Acquired Pneumonia (CAP) in children can lead to reduced lung diffusion capacity (TLCO). Early macrolide therapy is crucial for better pulmonary recovery.
Area of Science:
- Pediatric Pulmonology
- Infectious Diseases
- Respiratory Medicine
Background:
- Mycoplasma pneumoniae is an underdiagnosed cause of pediatric Community-Acquired Pneumonia (CAP).
- Delayed macrolide treatment is common for M. pneumoniae CAP.
- Pulmonary sequelae after pediatric CAP require further investigation.
Purpose of the Study:
- To estimate the frequency of pulmonary involvement in children 6 months after Mycoplasma CAP.
- To assess the impact of M. pneumoniae CAP on lung function.
- To correlate pulmonary function with treatment delay and duration.
Main Methods:
- Carbon monoxide diffusion capacity (TLCO) and spirometry were measured in 35 children (4.5-15 years) post-CAP.
- Follow-up assessments were conducted at 6 months and 1 year.
- Children with M. pneumoniae CAP were compared to those with pneumococcal or viral pneumonia.
Main Results:
- All children had normal lung volumes and spirometry.
- TLCO was normal post-pneumococcal or viral pneumonia.
- 48% of children with M. pneumoniae CAP had reduced TLCO (<80% of expected) at 6 months.
- Reduced TLCO correlated with delayed diagnosis (>10 days) and shorter macrolide therapy (<2 weeks).
Conclusions:
- Reduced pulmonary gas diffusion (abnormal TLCO) can persist after Mycoplasma pneumonia recovery in children.
- Delayed diagnosis and insufficient macrolide therapy are associated with impaired lung function.
- Early and adequate macrolide treatment is essential for optimal recovery from pediatric M. pneumoniae CAP.